Question: I have recently been diagnosed with sciatica and I am finding it difficult to do any exercise. My usual form of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

"FDA approves Vertex’s acute pain treatment Journavx" was originally created and published by Pharmaceutical Technology, a ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

An archived webcast will be available on the company's website. About the Phase 2 Suzetrigine Lumbosacral Radiculopathy (LSR) Study This phase 2, 12-week, randomized, double-blind, placebo ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...